8-K: Elevance Health Reports Mixed Second Quarter Results Amid Medicaid Attrition

Elevance Health's second quarter 2024 results show a slight decrease in operating revenue, offset by growth in other areas, and a 26% increase in diluted EPS.

Summary

• Elevance Health reported a second quarter operating revenue of $43.2 billion, a slight decrease from $43.4 billion in the same quarter last year.
• The company's adjusted operating gain was $2.8 billion.
• Diluted earnings per share (EPS) increased by 26% to $9.85, while adjusted diluted EPS rose by 12% to $10.12.
• Medicaid membership attrition led to a decrease in overall medical membership by 2.2 million, or 5%, compared to the prior year.
• This membership decline was partially offset by growth in Affordable Care Act health plans and commercial Employer Group fee-based membership.
• The benefit expense ratio improved slightly to 86.3%, while the operating expense ratio increased to 11.7%.
• Operating cash flow was $2.4 billion year-to-date, a decrease of $6.0 billion year-over-year, including $4.3 billion of timing-related items.
• Elevance Health expects GAAP net income per diluted share to be at least $34.05 in 2024, and adjusted diluted net income per share to be at least $37.20.
• The company repurchased 0.9 million shares of its common stock for $462 million during the quarter and declared a third quarter dividend of $1.63 per share.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there are some challenges, such as the decrease in Medicaid membership and operating cash flow, the company has shown growth in other areas, maintained its full-year outlook, and increased EPS. The company is navigating a complex environment, but the overall tone is cautiously optimistic.

Positives

• Diluted EPS increased by 26% year-over-year to $9.85.
• Adjusted diluted EPS increased by 12% year-over-year to $10.12.
• The benefit expense ratio improved slightly to 86.3%.
• Carelon segment operating revenue increased by 10% year-over-year to $13.3 billion.
• Carelon's operating gain increased by 8% year-over-year.
• The company has $3.2 billion remaining in its share repurchase authorization.
• Elevance Health maintained its full-year outlook.

Negatives

• Operating revenue decreased slightly by $0.2 billion year-over-year to $43.2 billion.
• Medical membership decreased by 2.2 million, or 5%, year-over-year.
• Operating cash flow decreased by $6.0 billion year-over-year to $2.4 billion year-to-date.
• The operating expense ratio increased by 60 basis points to 11.7%.
• Medicaid membership attrition was a significant factor in the overall membership decline.

Risks

• Trends in healthcare costs and utilization rates could impact profitability.
• Reduced enrollment could negatively affect revenue.
• The company's ability to secure and implement sufficient premium rates is crucial.
• Large-scale medical emergencies, such as pandemics, pose a risk.
• Changes in laws and regulations could impact the business.
• Cyber-attacks and data security incidents are a potential threat.
• Failure to maintain and modernize information systems could disrupt operations.
• Competitive pressures and the ability to adapt to industry changes are ongoing concerns.
• Risks associated with Medicare and Medicaid programs could affect revenue.
• Litigation, government investigations, and audits could lead to liabilities.
• The company's substantial debt and interest rate volatility could impact financing costs.
• Negative publicity could affect the company's reputation and business.
• Intense competition for talent could impact operations.

Future Outlook

Elevance Health has maintained its full-year outlook and is confident in the earnings power of its Health Benefits and Carelon businesses, expecting GAAP net income per diluted share to be at least $34.05 and adjusted diluted net income per share to be at least $37.20 for 2024.

Management Comments

• Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity.
• We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which underpin our long-term targets.

Industry Context

The results reflect a challenging period for the health insurance industry, with Medicaid membership attrition impacting overall growth, while the company is seeing growth in other areas such as the Affordable Care Act and Carelon segments. The company is navigating a dynamic environment with a focus on strategic initiatives and cost management.

Comparison to Industry Standards

• UnitedHealth Group (UNH), a major competitor, also faces similar challenges in managing medical costs and membership fluctuations, but has a larger market share and more diversified revenue streams.
• Humana (HUM) is another key competitor, particularly in the Medicare space, and is also navigating changes in government programs and healthcare utilization.
• CVS Health (CVS), while having a different business model with its pharmacy and retail operations, competes with Elevance Health in the pharmacy benefits management space through CarelonRx.
• Elevance Health's operating margin of 6.4% is comparable to industry averages, but the company's focus on cost management and strategic investments will be crucial for future performance.
• The decrease in Medicaid membership is a common trend across the industry due to eligibility redeterminations, and Elevance Health's performance in this area is consistent with its peers.

Stakeholder Impact

• Shareholders will receive a third quarter dividend of $1.63 per share.
• Shareholders may be impacted by the decrease in operating cash flow and Medicaid membership.
• Employees may be impacted by the company's focus on cost management.
• Customers may be impacted by changes in healthcare costs and utilization rates.
• Suppliers may be impacted by the company's focus on cost management.
• Creditors may be impacted by the company's substantial debt and interest rate volatility.

Next Steps

• Management will continue to focus on strategic initiatives and cost management.
• The company will continue to monitor healthcare costs and utilization rates.
• Elevance Health will work to mitigate the impact of Medicaid membership attrition.
• The company will continue to invest in its Carelon business.
• Elevance Health will continue to execute its share repurchase program.

Key Dates

Keywords

Elevance Health, Healthcare, Health Insurance, Earnings, Financial Results, Medicaid, Medicare, Carelon, EPS, Operating Revenue, Membership, Dividends, Share Repurchase